The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.

Hum Vaccin ImmunotherJul 6, 2026 (epub)
Clinical ResearchOncology (Medical)Preventive Medicine / Public HealthOpen access

Fakher Rahim, Ümit Atasever

✦ AI-curated · Sources linked

In 30 seconds

This umbrella review synthesizes data from 34 meta-analyses to evaluate the impact of HPV vaccination on cancer and pre-cancer outcomes. The review found that in HPV-naïve women, the vaccine demonstrated 99% efficacy against HPV16/18 infection and 96% against CIN2+. The study highlights the vaccine's effectiveness across various populations and outcomes.

Key findings

  • HPV vaccination showed 99% efficacy against HPV16/18 infection in HPV-naïve women.
  • The vaccine demonstrated 96% efficacy against CIN2+ lesions.
  • Ecological studies indicated a 57-88% reduction in cervical cancer rates.
  • In men, the vaccine's effectiveness against anogenital warts ranged from 74-90%.

Why it matters

Understanding the population-level impact of HPV vaccination is crucial for public health strategies aimed at reducing the incidence of HPV-related cancers and precancerous lesions. This evidence supports the continued promotion of vaccination programs.

Source

PubMed · PMID 42409728Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.